Strategic Partnership Opportunity to leverage existing Baylor licensing history to pursue co-development or distribution partnerships with academic medical centers and affiliated hospitals that are already familiar with Ox66 and its potential.

Regulatory Pathway Ox66 is in the process of FDA approval; engage with regulatory affairs teams at target buyers and contract manufacturers to align on data needs, potential outcomes, and timelines to accelerate adoption once approved.

Clinical Adoption Target healthcare providers and research institutions focused on oxygenation therapies and critical care, highlighting Ox66’s soluble oxygen powder advantages as a novel therapeutic modality.

Manufacturing Readiness Identify GMP-compatible manufacturing and supply chain partners or contract manufacturers familiar with specialty oxygenated compounds to support scale if Ox66 moves toward commercialization.

Market Expansion Position Ox66 for use across multiple markets and potential indications by mapping adjacent verticals such as wound healing, emergency medicine, and preventive health to broaden commercial opportunities.